The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
Open accessAbstract
Immunotherapy, where the patient’s own immune system is exploited to eliminate tumor cells, has become one of the most prominent new cancer treatment options in the last decade. The main hurdle for classical cancer vaccines is the need to identify tumor- and patient specific antigens to include in the vaccine. Therefore, in situ vaccination represents an alternative and promising approach. This type of immunotherapy involves the direct intratumoral administration of different immunomodulatory agents and uses the tumor itself as the source of antigen. The ultimate aim is to convert an immunosuppressive tumor microenvironment into an immunostimulatory one, enabling the immune system to eradicate all tumor lesions in the body. In this review we will give an overview of different strategies that can be exploited for in situ vaccination and their emerging role in the treatment of cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 17×
“Due to the heterogeneity within tumors and since cancer vaccines only target a limited number of antigens, cancer cells that do not express these antigens can escape immune control and give rise to new tumor populations that can resist treatment with a vaccine encoding the same TAAs (9).”
BackgroundInfluentialPhotodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145 · cited 1×
“of the cases PDT is used in combination with other standard of care therapies (86).”
MethodCyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Hyperthermia in combined treatment of cancer
Wust, P., Hildebrandt, B., Sreenivasa, G., Rau, B., Gellermann, J., Riess, H., Felix, R., & Schlag, P. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00818-5 · Cited by 1,998
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
cGAS surveillance of micronuclei links genome instability to innate immunity
Mackenzie, K. J., Carroll, P., Martin, C.-A., Murina, O., Fluteau, A., Simpson, D. J., Olova, N., Sutcliffe, H., Rainger, J. K., Leitch, A., et al. (2017) · Nature · doi:10.1038/nature23449 · Cited by 1,752
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases
Mempel, T. R., Henrickson, S. E., & von Andrian, U. H. (2004) · Nature · doi:10.1038/nature02238 · Cited by 1,714
Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Elgueta, R., Benson, M. J., De Vries, V. C., Wasiuk, A., Guo, Y., & Noelle, R. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00782.x · Cited by 1,625
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508
Gardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., Murphy-Ullrich, J. E., Bratton, D. L., Oldenborg, P.-A., Michalak, M., & Henson, P. M. (2005) · Cell · doi:10.1016/j.cell.2005.08.032 · Cited by 1,473
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?
Lutz, M. B., & Schuler, G. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02281-0 · Cited by 1,349
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313 · cited 1×
“After phagocytosis of the tumor cells, the partially degraded genomic DNA, which was compartmentalized in the nucleus, is efficiently processed by DNase II in the lysosomal compartment (41, 42).”
BackgroundAcquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Innate immunity to virus infection
Takeuchi, O., & Akira, S. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00737.x · Cited by 1,229
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Whole Body Irradiation—Radiobiology or Medicine?
Mole, R. H. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-305-234 · Cited by 1,123
Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis
Chekeni, F. B., Elliott, M. R., Sandilos, J. K., Walk, S. F., Kinchen, J. M., Lazarowski, E. R., Armstrong, A. J., Penuela, S., Laird, D. W., Salvesen, G. S., et al. (2010) · Nature · doi:10.1038/nature09413 · Cited by 1,120
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,092
Weller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 4×
“A danger signal that is detected by endosomal TLR3 and the intracellular sensors RIG-I and MDA-5 is dsRNA (149).”
BackgroundInfluentialDemaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
Radiation oncology in the era of precision medicine
Baumann, M., Krause, M., Overgaard, J., Debus, J., Bentzen, S. M., Daartz, J., Richter, C., Zips, D., & Bortfeld, T. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.18 · Cited by 812
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
Heavy-ion tumor therapy: Physical and radiobiological benefits
Schardt, D., Elsässer, T., & Schulz-Ertner, D. (2010) · Reviews of Modern Physics · doi:10.1103/revmodphys.82.383 · Cited by 778
Charged particles in radiation oncology
Durante, M., & Loeffler, J. S. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.183 · Cited by 737
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron, T. O., Babb, J. S., Schneider, R. J., Formenti, S. C., Dustin, M. L., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3099 · Cited by 711
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Golden, E. B., Chhabra, A., Chachoua, A., Adams, S., Donach, M., Fenton-Kerimian, M., Friedman, K., Ponzo, F., Babb, J. S., Goldberg, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00054-6 · Cited by 667
Sharabi, A. B., Nirschl, C. J., Kochel, C. M., Nirschl, T. R., Francica, B. J., Velarde, E., Deweese, T. L., & Drake, C. G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0196 · Cited by 658
Atkins, M. B., Robertson, M. J., Gordon, M. S., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D. J., Garzone, P. D., et al. (1997) · PubMed · Cited by 583
Nanotechnology in hyperthermia cancer therapy: From fundamental principles to advanced applications
Beik, J., Abed, Z., Ghoreishi, F. S., Hosseini-Nami, S., Mehrzadi, S., Shakeri-Zadeh, A., & Kamrava, S. K. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.062 · Cited by 579
Puzanov, I., Milhem, M. M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K. S., Anderson, A., Chou, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1529 · Cited by 562
Magnetic nanoparticle-based hyperthermia for cancer treatment
Bañobre-López, M., Teijeiro, A., & Rivas, J. (2013) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2013.09.011 · Cited by 545
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
Programmed cell death and the immune system
Nagata, S., & Tanaka, M. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.153 · Cited by 512
Moresco, E. M. Y., LaVine, D., & Beutler, B. (2011) · Current Biology · doi:10.1016/j.cub.2011.05.039 · Cited by 500 · cited 16×
“Moreover, RT can overcome T cell exclusion from the tumor by promoting the release of chemokines that attract effector T cells to the Frontiers in Immunology | www.frontiersin.org 4 December 2018 | Volume 9 | Article 2909 TME.”
BackgroundInfluentialImage-guided radiotherapy: from current concept to future perspectives
Jaffray, D. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.194 · Cited by 496
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Curti, B. D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., Walker, J., Gonzalez, I., Meeuwsen, T., Fox, B. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4174 · Cited by 496
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 487
Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity
Lugade, A. A., Sorensen, E. W., Gerber, S. A., Moran, J. P., Frelinger, J. G., & Lord, E. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3132 · Cited by 485
In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
Lizotte, P. H., Wen, A. M., Sheen, M. R., Fields, J., Rojanasopondist, P., Steinmetz, N. F., & Fiering, S. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.292 · Cited by 485
Filatenkov, A., Baker, J., Mueller, A. M. S., Kenkel, J., Ahn, G.-O., Dutt, S., Zhang, N., Kohrt, H., Jensen, K., Dejbakhsh-Jones, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2824 · Cited by 474
Electrochemotherapy in treatment of tumours
Sersa, G., Miklavcic, D., Cemazar, M., Rudolf, Z., Pucihar, G., & Snoj, M. (2008) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2007.05.016 · Cited by 459
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452
An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012) · Science · doi:10.1126/science.1224922 · Cited by 436
Transforming growth factor-beta activation in irradiated murine mammary gland.
Barcellos-Hoff, M. H., Derynck, R., Tsang, M. L., & Weatherbee, J. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117045 · Cited by 431
Radiation Enhances Regulatory T Cell Representation
Kachikwu, E. L., Iwamoto, K. S., Liao, Y.-P., DeMarco, J. J., Agazaryan, N., Economou, J. S., McBride, W. H., & Schaue, D. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.09.034 · Cited by 429
Charged particle therapy—optimization, challenges and future directions
Loeffler, J. S., & Durante, M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.79 · Cited by 426
Gameiro, S. R., Jammeh, M. L., Wattenberg, M. M., Tsang, K. Y., Ferrone, S., & Hodge, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.1719 · Cited by 415
Tumor-Treating Fields: A Fourth Modality in Cancer Treatment
Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D., & Von Hoff, D. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1117 · Cited by 380
Radiotherapy: Changing the Game in Immunotherapy
Demaria, S., Coleman, C. N., & Formenti, S. C. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.002 · Cited by 363
Regnier, R. (1992) · PubMed · Cited by 362
Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs
Diamond, J. M., Vanpouille-Box, C., Spada, S., Rudqvist, N.-P., Chapman, J. R., Ueberheide, B. M., Pilones, K. A., Sarfraz, Y., Formenti, S. C., & Demaria, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0581 · Cited by 358
Rationale for anti-OX40 cancer immunotherapy
Aspeslagh, S., Postel-Vinay, S., Rusakiewicz, S., Soria, J.-C., Zitvogel, L., & Marabelle, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.021 · Cited by 318
Parato, K. A., Breitbach, C. J., Le Boeuf, F., Wang, J., Storbeck, C., Ilkow, C., Diallo, J.-S., Falls, T., Burns, J., Garcia, V., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.276 · Cited by 305
Bacteriolytic therapy can generate a potent immune response against experimental tumors
Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J.-F., Drake, C. G., Hipkiss, E. L., Tatsumi, M., Dang, L. H., Diaz, L. A., Pomper, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406242101 · Cited by 304
Steel, G. G., McMillan, T. J., & Peacock, J. H. (1989) · International Journal of Radiation Biology · doi:10.1080/09553008914552491 · Cited by 290
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Engeland, C. E., Grossardt, C., Veinalde, R., Bossow, S., Lutz, D., Kaufmann, J. K., Shevchenko, I., Umansky, V., Nettelbeck, D. M., Weichert, W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.160 · Cited by 280
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer
Marelli, G., Howells, A., Lemoine, N. R., & Wang, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00866 · Cited by 279
Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis
Ohba, K., Omagari, K., Nakamura, T., Ikuno, N., Saeki, S., Matsuo, I., Kinoshita, H., Masuda, J., Hazama, H., Sakamoto, I., et al. (1998) · Gut · doi:10.1136/gut.43.4.575 · Cited by 277
Therapeutic hyperthermia: The old, the new, and the upcoming
Mallory, M., Gogineni, E., Jones, G. C., Greer, L., & Simone, C. B. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.003 · Cited by 258
RAGE and TLRs: Relatives, friends or neighbours?
Ibrahim, Z. A., Armour, C. L., Phipps, S., & Sukkar, M. B. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.07.008 · Cited by 257
Baird, J. R., Friedman, D., Cottam, B., Dubensky, T. W., Kanne, D. B., Bambina, S., Bahjat, K., Crittenden, M. R., & Gough, M. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3619 · Cited by 257
Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines
Russell, S. J., & Barber, G. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.011 · Cited by 244
Oncogene-induced senescence and tumour control in complex biological systems
Galluzzi, L., & Vitale, I. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-018-0102-y · Cited by 242
Wersäll, P. J., Blomgren, H., Pisa, P., Lax, I., Kälkner, K.-M., & Svedman, C. (2006) · Acta Oncologica · doi:10.1080/02841860600604611 · Cited by 233
Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally
Aznar, M. A., Tinari, N., Rullán, A. J., Sánchez-Paulete, A. R., Rodriguez-Ruiz, M. E., & Melero, I. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601145 · Cited by 230
Lee, J. M., Lee, M.-H., Garon, E., Goldman, J. W., Salehi-Rad, R., Baratelli, F. E., Schaue, D., Wang, G., Rosen, F., Yanagawa, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2821 · Cited by 228
Adams, S., Kozhaya, L., Martiniuk, F., Meng, T.-C., Chiriboga, L., Liebes, L., Hochman, T., Shuman, N., Axelrod, D., Speyer, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1149 · Cited by 222
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
Cheema, T. A., Wakimoto, H., Fecci, P. E., Ning, J., Kuroda, T., Jeyaretna, D. S., Martuza, R. L., & Rabkin, S. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307935110 · Cited by 221
Jackaman, C., Bundell, C. S., Kinnear, B. F., Smith, A. M., Filion, P., van Hagen, D., Robinson, B. W. S., & Nelson, D. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.5051 · Cited by 203
Fransen, M. F., van der Sluis, T. C., Ossendorp, F., Arens, R., & Melief, C. J. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0781 · Cited by 200
Jiang, H., Rivera-Molina, Y., Gomez-Manzano, C., Clise-Dwyer, K., Bover, L., Vence, L. M., Yuan, Y., Lang, F. F., Toniatti, C., Hossain, M. B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0468 · Cited by 197
Brix, N., Tiefenthaller, A., Anders, H., Belka, C., & Lauber, K. (2017) · Immunological Reviews · doi:10.1111/imr.12573 · Cited by 197
Kim, J.-Y., Son, Y.-O., Park, S.-W., Bae, J.-H., Chung, J. S., Kim, H. H., Chung, B.-S., Kim, S.-H., & Kang, C.-D. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.56 · Cited by 195
Park, S. H., Breitbach, C. J., Lee, J., Park, J. O., Lim, H. Y., Kang, W. K., Moon, A., Mun, J.-H., Sommermann, E. M., Maruri‐Avidal, L., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.109 · Cited by 195
Barriers to Radiation-Induced In Situ Tumor Vaccination
Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Pilones, K. A., García-Martínez, E., Rudqvist, N.-P., Formenti, S. C., & Demaria, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00229 · Cited by 194
Transforming growth factor-β in breast cancer: too much, too late
Barcellos-Hoff, M. H., & Akhurst, R. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2224 · Cited by 187
In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf
Hammerich, L., Binder, A., & Brody, J. D. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.016 · Cited by 187
Meng, Y., Beckett, M. A., Liang, H., Mauceri, H. J., van Rooijen, N., Cohen, K. S., & Weichselbaum, R. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2995 · Cited by 181
Voloshin, T., Kaynan, N., Davidi, S., Porat, Y., Shteingauz, A., Schneiderman, R. S., Zeevi, E., Munster, M., Blat, R., Tempel Brami, C., et al. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02534-7 · Cited by 179
Houot, R., & Levy, R. (2009) · Blood · doi:10.1182/blood-2008-07-170274 · Cited by 178
Tumor treating fields: A novel treatment modality and its use in brain tumors
Hottinger, A. F., Pacheco, P., & Stupp, R. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now182 · Cited by 177
Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation
Singh, M., Khong, H., Dai, Z., Huang, X.-F., Wargo, J. A., Cooper, Z. A., Vasilakos, J. P., Hwu, P., & Overwijk, W. W. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401160 · Cited by 166
Landscape of Tumor Antigens in T Cell Immunotherapy
Ilyas, S., & Yang, J. C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501657 · Cited by 163
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
Achard, C., Surendran, A., Wedge, M.-È., Ungerechts, G., Bell, J. C., & Ilkow, C. S. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.020 · Cited by 163
Dias, J. D., Hemminki, O., Diaconu, I., Hirvinen, M., Bonetti, A., Guse, K., Escutenaire, S., Kanerva, A., Pesonen, S. K., Loskog, A., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.176 · Cited by 162
Diaconu, I., Cerullo, V., Hirvinen, M. L. M., Escutenaire, S., Ugolini, M., Pesonen, S. K., Bramante, S., Parviainen, S., Kanerva, A., Loskog, A. S. I., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2975 · Cited by 162
Designing and Building Oncolytic Viruses
Maroun, J., Muñoz-Alía, M., Ammayappan, A., Schulze, A., Peng, K.-W., & Russell, S. (2017) · Future Virology · doi:10.2217/fvl-2016-0129 · Cited by 161
Dewan, M. Z., Vanpouille‐Box, C., Kawashima, N., DiNapoli, S., Babb, J. S., Formenti, S. C., Adams, S., & Demaria, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0984 · Cited by 160
The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?
Hu, Z. I., McArthur, H. L., & Ho, A. Y. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0234-y · Cited by 160
Cripe, T. P., Ngo, M. C., Geller, J. I., Louis, C. U., Currier, M. A., Racadio, J. M., Towbin, A. J., Rooney, C. M., Pelusio, A., Moon, A., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.243 · Cited by 159
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
Türeci, Ö., Vormehr, M., Diken, M., Kreiter, S., Huber, C., & Şahin, U. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1509 · Cited by 157
Eriksson, E., Milenova, I. E., Wenthe, J., Ståhle, M., Leja-Jarblad, J., Ullenhag, G. J., Dimberg, A., Moreno, R., Alemany, R., & Loskog, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0285 · Cited by 154
Fransen, M. F., Sluijter, M., Morreau, H. M., Arens, R., & Melief, C. J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2888 · Cited by 153
Gameiro, S. R., Malamas, A. S., Bernstein, M. B., Tsang, K. Y., Vassantachart, A., Sahoo, N., Tailor, R. C., Pidikiti, R., Guha, C., Hahn, S. M., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.02.022 · Cited by 151
Weide, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T., Radny, P., Zelba, H., Pföhler, C., Pawelec, G., & Garbe, C. (2010) · Cancer · doi:10.1002/cncr.25156 · Cited by 148
Henrickson, S. E., Perro, M., Loughhead, S. M., Senman, B. C., Stutte, S., Quigley, M. M., Alexe, G., Iannacone, M., Flynn, M. P., Omid, S., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.034 · Cited by 145
Immunocytokines for cancer treatment: past, present and future
Neri, D., & Sondel, P. M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.006 · Cited by 145
Egilmez, N. K., Jong, Y. S., Sabel, M. S., Jacob, J. S., Mathiowitz, E., & Bankert, R. B. (2000) · PubMed · Cited by 143
Pesonen, S. A., Diaconu, I., Kangasniemi, L., Ranki, T., Kanerva, A., Pesonen, S. K., Gerdemann, U., Leen, A. M., Kairemo, K., Oksanen, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3001 · Cited by 140
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
Derer, A., Spiljar, M., Bäumler, M., Hecht, M., Fietkau, R., Frey, B., & Gaipl, U. S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00610 · Cited by 139
Havunen, R., Siurala, M., Sorsa, S., Grönberg-Vähä-Koskela, S. A. M., Behr, M., Tähtinen, S., Santos, J. M., Karell, P., Rusanen, J., Nettelbeck, D. M., et al. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2016.12.004 · Cited by 136
Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
Crittenden, M. R., Kohrt, H. E. K., Levy, R., Jones, J. C., Camphausen, K. A., Dicker, A. P., Demaria, S., & Formenti, S. C. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.003 · Cited by 135
Balogh, A., Persa, E., Bogdándi, E. N., Benedek, A., Hegyesi, H., Sáfrány, G., & Lumniczky, K. (2012) · Inflammation Research · doi:10.1007/s00011-012-0567-y · Cited by 133
Lint, S. V., Renmans, D., Broos, K., Goethals, L., Maenhout, S. K., Benteyn, D., Goyvaerts, C., Four, S. D., der Jeught, K. V., Bialkowski, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0163 · Cited by 130
Self-citationMorse, M. A., Nair, S. K., Fernandez-Casal, M., Deng, Y., Peter, M. S., Williams, R., Hobeika, A. C., Mosca, P. J., Clay, T. M., Cumming, R. I., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3883 · Cited by 127
Li, J., Song, W., Czerwinski, D. K., Varghese, B., Uematsu, S., Akira, S., Krieg, A. Μ., & Levy, R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2493 · Cited by 125
The effect of ionizing radiation on regulatory T cells in health and disease
Persa, E., Balogh, A., Sáfrány, G., & Lumniczky, K. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.003 · Cited by 123
Salazar, A. Μ., Erlich, R. B., Mark, A. S., Bhardwaj, N., & Herberman, R. B. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0024 · Cited by 122
Oncolytic Virotherapy: A Contest between Apples and Oranges
Russell, S. J., & Peng, K.-W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.026 · Cited by 122
Garg, A. D., Vandenberk, L., Fang, S., Fasche, T., Van Eygen, S., Maes, J., Van Woensel, M., Koks, C., Vanthillo, N., Graf, N., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.15 · Cited by 120
Expression of NF-κB p50 in Tumor Stroma Limits the Control of Tumors by Radiation Therapy
Crittenden, M. R., Cottam, B., Savage, T., Nguyen, C., Newell, P., & Gough, M. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039295 · Cited by 116
TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
Cervera-Carrascón, V., Siurala, M., Santos, J. M., Havunen, R., Tähtinen, S., Karell, P., Sorsa, S., Kanerva, A., & Hemminki, A. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1412902 · Cited by 112
Redondo, P., del Olmo, J., de Cerio, A. L.-D., Inogés, S., Marquina, M., Melero, I., & Bendandi, M. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700777 · Cited by 110
Varghese, S., Rabkin, S. D., Liu, R., Nielsen, P., Ipe, T. S., & Martuza, R. L. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700900 · Cited by 110
Anwer, K., Barnes, M. N., Fewell, J. G., Lewis, D. H., & Alvarez, R. D. (2009) · Gene Therapy · doi:10.1038/gt.2009.159 · Cited by 108
Kwilas, A. R., Donahue, R. N., Bernstein, M. B., & Hodge, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00104 · Cited by 107
Mangsbo, S. M., Broos, S., Fletcher, E. A. K., Veitonmäki, N., Furebring, C., Dahlén, E., Norlén, P., Lindstedt, M., Tötterman, T. H., & Ellmark, P. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0913 · Cited by 102
Galanis, E., Hersh, E. M., Stopeck, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3313 · Cited by 99
Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results
Granata, V., Fusco, R., Piccirillo, M. C., Palaia, R., Petrillo, A., Lastoria, S., & Izzo, F. (2015) · International Journal of Surgery · doi:10.1016/j.ijsu.2015.04.055 · Cited by 98
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives
Guo, Z. S., Liu, Z., Kowalsky, S. J., Feist, M., Kaliński, P., Lu, B., Storkus, W. J., & Bartlett, D. L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00555 · Cited by 98
Cerullo, V., Diaconu, I., Romano, V. C., Hirvinen, M., Ugolini, M., Escutenaire, S., Holm, L., Kipar, A., Kanerva, A., & Hemminki, A. (2012) · Molecular Therapy · doi:10.1038/mt.2012.137 · Cited by 97
Hanes, J. S., Sills, A. K., Zhao, Z., Suh, K., Tyler, B., DiMeco, F., Brat, D. J., Choti, M. A., Leong, K. W., Pardoll, D. M., et al. (2001) · Pharmaceutical Research · doi:10.1023/a:1010963307097 · Cited by 94
Particle-Mediated Delivery of Cytokines for Immunotherapy
Christian, D. A., & Hunter, C. A. (2012) · Immunotherapy · doi:10.2217/imt.12.26 · Cited by 93
Breitbach, C. J., Moon, A., Burke, J., Hwang, T.-H., & Kirn, D. H. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2727-2_19 · Cited by 92
Electrochemotherapy in the Treatment of Bone Metastases: A Phase II Trial
Bianchi, G., Campanacci, L., Ronchetti, M., & Donati, D. M. (2016) · World Journal of Surgery · doi:10.1007/s00268-016-3627-6 · Cited by 83
CCL22 and CCL17 in rat radiation pneumonitis and in human idiopathic pulmonary fibrosis
Inoue, T., Fujishima, S., Ikeda, E., Yoshie, O., Tsukamoto, N., Aiso, S., Aikawa, N., Kubo, A., Matsushima, K., & Yamaguchi, K. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00110203 · Cited by 81
Does Heavy Ion Therapy Work Through the Immune System?
Durante, M., Brenner, D. J., & Formenti, S. C. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.08.037 · Cited by 80
First Oncolytic Viral Therapy for Melanoma
Poh, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2015-158 · Cited by 79
Rhines, L. D., Sampath, P., DiMeco, F., Lawson, H. C., Tyler, B., Hanes, J. S., Olivi, A., & Brem, H. (2003) · Neurosurgery · doi:10.1227/01.neu.0000053211.39087.d1 · Cited by 75
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
TTFields: where does all the skepticism come from?
Wick, W. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now012 · Cited by 72
Marroquin, C. E., Westwood, J. A., Lapointe, R., Mixon, A., Wunderlich, J. R., Caron, D. A., Rosenberg, S. A., & Hwu, P. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200205000-00011 · Cited by 70
Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines
Saxena, M., & Bhardwaj, N. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.06.003 · Cited by 60
Du, T., Shi, G., Li, Y., ZHANG, J. F., Tian, H., Wei, Y., Deng, H., & Yu, D. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.34 · Cited by 55
Lee, H. J., Zeng, J., & Rengan, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.03.28 · Cited by 55
Spaner, D., Miller, R. L., Mena, J., et al. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500054426 · Cited by 54
Electrochemotherapy of Tumours
Serša, G., & Miklavčič, D. (2008) · Journal of Visualized Experiments · doi:10.3791/1038-v · Cited by 53
Nasi, M. L., Lieberman, P., BUSAM, K. J., Prieto, V., Panageas, K. S., Lewis, J. J., Houghton, A. N., & Chapman, P. B. (1999) · PubMed · Cited by 51
Liposomal Drug Delivery System for Cancer Therapy: Advancement and Patents
Jha, S., Sharma, P. K., & Malviya, R. (2016) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/1872211310666161004155757 · Cited by 47
TLR Agonists as Adjuvants for Cancer Vaccines
Li, J., Balic, J. J., Yu, L., & Jenkins, B. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-5987-2_9 · Cited by 47
Crittenden, M. R., Savage, T., Cottam, B., Bahjat, K. S., Redmond, W. L., Bambina, S., Kasiewicz, M. J., Newell, P., Jackson, A. M., & Gough, M. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069527 · Cited by 46
Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity
Raykov, Z., Grekova, S. P., Leuchs, B., Aprahamian, M., & Rommelaere, J. (2008) · International Journal of Cancer · doi:10.1002/ijc.23472 · Cited by 46
Shimokawa, T., Ma, L., Ando, K., Sato, K., & Imai, T. (2016) · International Journal of Particle Therapy · doi:10.14338/ijpt-15-00023.1 · Cited by 46
Ebner, D. K., Kamada, T., & Yamada, S. (2017) · Advances in Radiation Oncology · doi:10.1016/j.adro.2017.06.001 · Cited by 46
Elsedawy, N. B., & Russell, S. J. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.836912 · Cited by 43
Hebb, J. P. O., Mosley, A. R., Vences‐Catalán, F., Rajasekaran, N., Rosén, A., Ellmark, P., & Felsher, D. W. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2059-y · Cited by 42
Electrochemotherapy in Breast Cancer: A Review of References
Schmidt, G., Juhasz‐Böss, I., Solomayer, E., & Herr, D. J. (2014) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0034-1368538 · Cited by 38
Kamenšek, U., Čemažar, M., Tratar, U. L., Uršič, K., & Serša, G. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2133-0 · Cited by 38
Pilones, K. A., Aryankalayil, J. B., Babb, J. S., & Demaria, S. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0037-x · Cited by 34
Perilumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma
Gutwald, J., Groth, W., & Mahrle, G. (1994) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1994.tb03397.x · Cited by 31
Small molecule immuno-oncology therapeutic agents
Toogood, P. L. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.044 · Cited by 30
Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod
Stavrakoglou, A., Brown, V. L., & Coutts, I. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07976.x · Cited by 15
Ruf, B., & Lauer, U. M. (2015) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2015.18 · Cited by 13
Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients
Balan, S., Finnigan, J. P., & Bhardwaj, N. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000251 · Cited by 12
Giladi, M., Voloshin, T., Shteingauz, A., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.196.supp.75.26 · Cited by 8
IMST-26. TUMOR TREATING FIELDS EXPOSURE OF TUMOR CELLS INDUCE ACTIVATION PHENOTYPE IN IMMUNE CELLS
Holtzman, T. S. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now212.382 · Cited by 8
Cited by
Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy
Jarosz-Biej, M., Smolarczyk, R., Cichoń, T., & Kułach, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133212 · Cited by 546
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
Zhang, W., Huang, Q., Xiao, W., Zhao, Y., Pi, J., Xu, H., Zhao, H., Xu, J., Evans, C. E., & Jin, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00018 · Cited by 353
Endothelial Cells in the Tumor Microenvironment
Sobierajska, K., Ciszewski, W. M., Sacewicz-Hofman, I., & Niewiarowska, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_6 · Cited by 179
Immunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
Metadata
- Authors
- Locy, H., de Mey, S., de Mey, W., De Ridder, M., Thielemans, K., & Maenhout, S. K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-12-11
- Volume
- 9
- Pages
- 2909-2909
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2904370205
- Cited by
- 279
- References
- 179
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.